IN VITRO SCREENING OF POTENTIAL CHEMOPREVENTIVE AGENTS

潜在化学预防剂的体外筛选

基本信息

项目摘要

Initial growth inhibition assays with the test chemopreventive agent are being used to select appropriate concentration ranges for use in the subsequent transformation-inhibition assay. Five log dilutions are used from 1 mM or the highest soluble concentration in medium or in a solvent such as dimethylsulfoxide without solvent toxicity. primary prostate epithelial cells are seeded into 60 mm dishes and allowed to attach for 24 hours. Then the chemopreventive test agent is added in fresh medium and the cultures allowed to incubate 72 hours then all cultures receive fresh media containing only the chemopreventive agent and incubated for 3-5 more days. A positive control compound such as a retinoid is used in all assays. Then the cultures are then fixed and stained. Three dishes per point are scored and the relative growth determined. The induction of apoptosis is being measured in human prostate epithelial cells. The level of induction of apoptosis is being measured in response to exposure to potential chemopreventive agents. Five nontoxic concentrations are being measured for their ability to induce apoptosis for each agent. The Inhibition of Prostate Specific Antigen (PSA) is being measured. A prostate specific antigen assay is being used to quantitatively measure effects of chemopreventive agents on the production of PSA in cultures of human prostate epithelial cells. At least 5 nontoxic concentrations are being tested for each compound.
初步生长抑制试验与试验化学预防剂

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mark E Stearns其他文献

Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t<sub>Δ773–1081</sub> overexpression is diagnostic for sentinel lymph node metastasis
  • DOI:
    10.1038/labinvest.3700075
  • 发表时间:
    2004-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Mark E Stearns;Min Wang;Youji Hu;Greq Kim;Fernando U Garcia
  • 通讯作者:
    Fernando U Garcia

Mark E Stearns的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mark E Stearns', 18)}}的其他基金

IL10 and IGF1 Receptor Axis in Prostate Cancer
前列腺癌中的 IL10 和 IGF1 受体轴
  • 批准号:
    6756456
  • 财政年份:
    2001
  • 资助金额:
    $ 45.71万
  • 项目类别:
IL10 and IGF1 Receptor Axis in Prostate Cancer
前列腺癌中的 IL10 和 IGF1 受体轴
  • 批准号:
    6318053
  • 财政年份:
    2001
  • 资助金额:
    $ 45.71万
  • 项目类别:
IL10 and IGF1 Receptor Axis in Prostate Cancer
前列腺癌中的 IL10 和 IGF1 受体轴
  • 批准号:
    6514956
  • 财政年份:
    2001
  • 资助金额:
    $ 45.71万
  • 项目类别:
IL10 and IGF1 Receptor Axis in Prostate Cancer
前列腺癌中的 IL10 和 IGF1 受体轴
  • 批准号:
    6895464
  • 财政年份:
    2001
  • 资助金额:
    $ 45.71万
  • 项目类别:
IL10 and IGF1 Receptor Axis in Prostate Cancer
前列腺癌中的 IL10 和 IGF1 受体轴
  • 批准号:
    6603132
  • 财政年份:
    2001
  • 资助金额:
    $ 45.71万
  • 项目类别:
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
IL-10 对前列腺癌淋巴管生成的调节
  • 批准号:
    7122505
  • 财政年份:
    1998
  • 资助金额:
    $ 45.71万
  • 项目类别:
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
IL-10 对前列腺癌淋巴管生成的调节
  • 批准号:
    7369898
  • 财政年份:
    1998
  • 资助金额:
    $ 45.71万
  • 项目类别:
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
IL-10 对前列腺癌淋巴管生成的调节
  • 批准号:
    6771264
  • 财政年份:
    1998
  • 资助金额:
    $ 45.71万
  • 项目类别:
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
IL-10 对前列腺癌淋巴管生成的调节
  • 批准号:
    6890003
  • 财政年份:
    1998
  • 资助金额:
    $ 45.71万
  • 项目类别:
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
IL-10 对前列腺癌淋巴管生成的调节
  • 批准号:
    7235661
  • 财政年份:
    1998
  • 资助金额:
    $ 45.71万
  • 项目类别:

相似海外基金

Evaluating the effectiveness and sustainability of integrating helminth control with seasonal malaria chemoprevention in West African children
评估西非儿童蠕虫控制与季节性疟疾化学预防相结合的有效性和可持续性
  • 批准号:
    MR/X023133/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.71万
  • 项目类别:
    Fellowship
Targeting cancer stem-like cells and inflammation for colon cancer chemoprevention
针对癌症干细胞样细胞和炎症进行结肠癌化学预防
  • 批准号:
    10650910
  • 财政年份:
    2023
  • 资助金额:
    $ 45.71万
  • 项目类别:
Examining the mechanisms and optimization of malaria chemoprevention strategies to improve birth outcomes in Africa
检查疟疾化学预防策略的机制和优化,以改善非洲的出生结果
  • 批准号:
    10642646
  • 财政年份:
    2023
  • 资助金额:
    $ 45.71万
  • 项目类别:
Targeting oncogenic pathways for chemoprevention of head and neck cancer by FLLL12
通过 FLLL12 靶向致癌途径对头颈癌进行化学预防
  • 批准号:
    10497514
  • 财政年份:
    2023
  • 资助金额:
    $ 45.71万
  • 项目类别:
Chemoprevention of HCC related to MAFLD
与 MAFLD 相关的 HCC 的化学预防
  • 批准号:
    10410751
  • 财政年份:
    2022
  • 资助金额:
    $ 45.71万
  • 项目类别:
"Investigating the rebound effects of seasonal malaria chemoprevention (SMC) in Mali"
“调查马里季节性疟疾化学预防 (SMC) 的反弹效果”
  • 批准号:
    10451972
  • 财政年份:
    2022
  • 资助金额:
    $ 45.71万
  • 项目类别:
Chemoproteomics and molecular dynamics simulation-based drug discovery platforms for chemoprevention
基于化学蛋白质组学和分子动力学模拟的化学预防药物发现平台
  • 批准号:
    22K10489
  • 财政年份:
    2022
  • 资助金额:
    $ 45.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of chemoprevention of cancer by drug repurposing with the macrolides
通过大环内酯类药物重新利用来开发癌症化学预防
  • 批准号:
    22K10490
  • 财政年份:
    2022
  • 资助金额:
    $ 45.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
  • 批准号:
    10677989
  • 财政年份:
    2022
  • 资助金额:
    $ 45.71万
  • 项目类别:
Chemoprevention of HCC related to MAFLD
与 MAFLD 相关的 HCC 的化学预防
  • 批准号:
    10657423
  • 财政年份:
    2022
  • 资助金额:
    $ 45.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了